IP Library Patent Application 16807769
Patent Application
App. No. 16/807,769

Prediction of Likelihood of Cancer Recurrence

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/807,769
Abstract

The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.

Claims (16)

1 .- 40 . (canceled)

41 . A method for analyzing the expression of genes in a human breast cancer patient, comprising:

obtaining a fixed, wax-embedded tissue sample from a breast cancer patient;

extracting RNA from the tissue sample;

reverse transcribing RNA transcripts of a set of genes consisting of 15-25 genes, wherein the set includes the following genes: (a) each of Ki-67, STK15, SURV, CCNB1, MYBL2, and STMY3, and (b) at least one reference gene, to produce cDNAs of the RNA transcripts of the set of genes; and

amplifying the cDNAs to produce amplicons from the cDNAs for determination of amplicon.

42 . The method of claim 41 , wherein the amplicon levels have been normalized against an amplicon level of an RNA transcript of at least one reference gene in the tissue sample.

43 . The method of claim 41 , wherein the amplicon levels are threshold cycle (Ct) values.

44 . The method of claim 41 , wherein the breast cancer patient has invasive, ductal carcinoma.

45 . The method of claim 41 , wherein the breast cancer patient has node negative and ER positive breast cancer.

46 . The method of claim 44 , wherein the breast cancer patient has node negative and ER positive breast cancer.

47 . The method of claim 41 , wherein the breast cancer patient has been treated with tamoxifen.

48 . The method of claim 44 , wherein the breast cancer patient has been treated with tamoxifen.

49 . The method of claim 41 , wherein the tissue sample comprises core biopsy or fine needle aspirate cells.

50 . The method of claim 41 , wherein the set of genes consists of 20 genes.

51 . The method of claim 41 , wherein the at least one reference gene comprises GADPH.